Stalevo: Clinical Trials

21 trials of Stalevo, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 3 unknown, 1 terminated, 1 withdrawn. 8 Phase 4, 6 Phase 1, 3 Phase 2, 3 Phase 3, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 48Completed 4, Unknown 2, Terminated 1, Withdrawn 1
Phase 16Completed 6
Phase 23Completed 3
Phase 33Completed 3
Not applicable1Unknown 1

Follow Stalevo: new trials by email Literature Review of Stalevo trials Research Report on Stalevo

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease
levodopa/carbidopa/entacapone - Parkinson Disease
Phase 4UnknownSecond Affiliated Hospital of Soochow University602023-11-152024-02-01
Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease
Stalevo, Carbidopa and Levodopa Controlled Release Tablets - Parkinson Disease
Phase 4UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine1802022-01-012023-02-16
Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)
Stalevo, levodopa MR - Parkinson's Disease
Phase 2CompletedOrion Corporation, Orion Pharma842016-04-082018-04-05
Pharmacokinetic Study in Healthy Volunteers
levodopa, carbidopa, ODM-104, levodopa, carbidopa, entacapone - Parkinson's Disease
Phase 1CompletedOrion Corporation, Orion Pharma152015-08-012016-01-14
Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease
Stalevo® - Parkinson Disease, Sleep Disorders
Not applicableUnknownAsan Medical Center1002015-03-012016-07-13
Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations
ODM-101 65mg Carbidopa, ODM-101 105mg Carbidopa, Stalevo - Parkinson's Disease
Phase 2CompletedOrion Corporation, Orion Pharma1172011-05-012013-11-21
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
IPX066, CLE - Parkinson's Disease
Phase 3CompletedImpax Laboratories, LLC1102010-05-012019-10-29
Levodopa Concentration Profile With Stalevo 75/125 mg
Stalevo (levodopa/ carbidopa/ entacapone), Sinemet (levodopa/carbidopa) - Parkinson's Disease
Phase 1CompletedOrion Corporation, Orion Pharma202009-12-012010-08-13
Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
carbidopa/levodopa, Carbidopa/Levodopa/Entacapone - Parkinson's Disease
Phase 4WithdrawnNovartis Pharmaceuticals2008-08-012012-04-30
Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off
Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa - Parkinson's Disease
Phase 4TerminatedNovartis142008-03-012011-02-18
Study to Evaluate Initiation of Stalevo in Early Wearing-off
Stalevo - Parkinson's Disease
Phase 4CompletedOrion Corporation, Orion Pharma1152006-09-012015-04-21
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers
ELC200 (carbidopa+levodopa+entacapone) - Healthy
Phase 1CompletedNovartis422006-07-012007-06-22
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone Under Fasting Conditions in Healthy Volunteers
ELC200 (carbidopa+levodopa+entacapone) - Healthy
Phase 1CompletedNovartis422006-06-012007-06-22
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers
ELC200 (carbidopa+levodopa+entacapone) - Healthy
Phase 1CompletedNovartis422006-06-012007-06-22
Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers
ELC200 (carbidopa+levodopa+entacapone) - Healthy
Phase 1CompletedNovartis422006-05-012007-06-22
Stalevo in Early Wearing-Off Patients
Stalevo (levodopa/carbidopa/entacapone), Levodopa/carbidopa - Idiopathic Parkinson's Disease
Phase 4CompletedOrion Corporation, Orion Pharma2232005-08-012009-06-22
A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa
capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) - Parkinson's Disease
Phase 3CompletedNovartis4932005-08-012017-05-17
Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States
carbidopa, levodopa, entacapone - Parkinson's Disease
Phase 4CompletedNovartis1842005-07-012017-03-29
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
Carbidopa/levodopa/entacapone - Parkinson's Disease With End of Dose Wearing Off
Phase 4CompletedNovartis Pharmaceuticals3592005-01-012017-03-30
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa - Parkinson's Disease
Phase 3CompletedNovartis Pharmaceuticals7472004-09-012012-04-23

Showing 20 of 21. Sign in to see all of them.

Conditions studied

Parkinson Disease (17)  ·  Dyskinesias (2)  ·  Fasting (1)  ·  Narcolepsy (1)  ·  Parasomnias (1)  ·  Sleep Wake Disorders (1)  ·  Tremor (1)

Sponsors

Novartis (7)  ·  Orion Corporation, Orion Pharma (6)  ·  Novartis Pharmaceuticals (3)  ·  Asan Medical Center (1)  ·  Impax Laboratories, LLC (1)  ·  Molecular NeuroImaging (1)  ·  Second Affiliated Hospital of Soochow University (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)

Countries

Germany (9)  ·  Finland (5)  ·  United States (5)  ·  Italy (3)  ·  Sweden (3)  ·  United Kingdom (3)  ·  Canada (2)  ·  China (2)  ·  France (2)  ·  Turkey (Türkiye) (2)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)  ·  Czechia (1)  ·  Denmark (1)

Top investigators

Aila Holopainen, MSc (1)  ·  Andrew Wighton, BSc (Hons) (1)  ·  Bhadravati SD Sastry, FRCP (1)  ·  Chun-Feng Liu, MD,PhD (1)  ·  Claudia Trenkwalder, MD (1)  ·  John P Seibyl, MD (1)  ·  Kimmo Ingman (1)  ·  Mika Scheinin, MD (1)  ·  Sun Ju Chung, Professor (1)  ·  Wolfgang H. Oertel, Professor (1)

Results publications

PMID 19058133, PMID 20582993, PMID 30425824, PMID 30824559